alexa The Pharmacokinetics of Fluticasone Furoate and Vilanterol Following Single Inhaled Administration in Combination and Intravenous Administration of Individual Components in Healthy Subjects
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

The Pharmacokinetics of Fluticasone Furoate and Vilanterol Following Single Inhaled Administration in Combination and Intravenous Administration of Individual Components in Healthy Subjects

Ann Allen1*, Ludovic Apoux2, Jo Bal2, Joseph Bianco3, Alison Moore2, Ramiya Ravindranath4, Lee Tombs5 and Rodger D Kempsford2

1GlaxoSmithKline R&D, Stevenage, United Kingdom

2GlaxoSmithKline R&D, Stockley Park, United Kingdom

3GlaxoSmithKline R&D, Abbotsford, Victoria, Australia

4GlaxoSmithKline R&D, QSI Bangalore, India

5Synergy, Slough, Berkshire, United Kingdom

*Corresponding Author:
Ann Allen
Clinical Pharmacology Modelling and Simulation
GlaxoSmithKline, Stevenage, SG1 2NY, UK
Tel: +44-1438-766-350
Fax: +44-1438-764-591
E-mail: [email protected]

Received Date: April 18, 2013; Accepted Date: June 18, 2013; Published Date: June 22, 2013

Citation: Allen A, Apoux L, Bal J, Bianco J, Moore A, et al. (2013) The Pharmacokinetics of Fluticasone Furoate and Vilanterol Following Single Inhaled Administration in Combination and Intravenous Administration of Individual Components in Healthy Subjects. J Bioequiv Availab 5:165-173. doi: 10.4172/jbb.1000153.

Copyright: © 2013 Allen A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Fluticasone furoate (FF)/vilanterol (VI), a novel inhaled corticosteroid/long-acting β 2 -agonist combination, is being developed as a once-daily inhaled treatment for asthma and chronic obstructive pulmonary disease. The two studies described here assess FF dose proportionality and VI equivalence across the clinical strengths of FF/ VI and the absolute bioavailability of the components administered as FF/VI in combination via the dry powder inhaler (DPI) intended for commercial use. Study 1 (NCT01213849) was a randomized, open-label, three-way crossover, single- dose study in healthy subjects designed to assess whether the systemic exposure of FF increased proportionately and VI systemic exposure was constant across different strength combinations of FF/VI (four inhalations of FF/ VI; 50/25 μg, 100/25 μg and 200/25 μg). Study 2 (NCT01299558) was an open-label, non-randomized, three- way crossover, single-dose study in healthy subjects conducted to determine the absolute bioavailability of FF/VI inhalation powder. Both FF and VI have high plasma clearance and extensive distribution into tissues. Overall, FF systemic exposure, as measured by AUC (0–t’) , was dose proportional over the 200-800 μg FF dose range. The less than dose proportional increase seen for FF C max is likely due to rate limited absorption from the lung. FF acts topically in the lung, whilst systemic exposure is related to safety. Consequently, the lack of dose proportionality for FF C max would be considered not to impact efficacy. Equivalence of VI exposure across the three FF/VI dosage strengths was demonstrated for AUC (0–t’) and C max . Following a single inhaled dose of FF/VI administered via DPI the absolute bioavailabilities of FF and VI were estimated to be 15% (90% confidence interval [CI]: 13%, 18%) and 27% (90% CI: 22%, 35%), respectively. FF showed longer retention in the lung than VI following inhaled administration, with the time for 90% of the total to be absorbed from the lung being on average 35.2 hours and 3.8 hours, respectively.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords